Core Viewpoint - *ST生物 is planning to acquire a 51% stake in Hunan Huize Biomedical Technology Co., Ltd. for cash, which will make Huize a subsidiary and included in the consolidated financial statements. This transaction is expected to constitute a significant asset restructuring as per the regulations [1] Group 1: Company Overview - Huize Biomedical is a professional CRO company focused on drug research and clinical evaluation, providing services such as pharmaceutical research, clinical trials, and data management statistical analysis [1] - Prior to the acquisition, *ST生物 primarily engaged in two business segments: "biomedical" and "energy conservation and environmental protection," along with the production and sales of other biomedical-related products [1] Group 2: Strategic Intent - The acquisition aims to extend the biomedical segment of *ST生物, enhancing the profitability of its main business and improving its risk resistance capabilities [1] - There is a strong correlation between cell clinical transformation research and drug development, and the asset integration is expected to improve operational efficiency and create significant synergies [1]

Group 1 - The technology sector is recommended as a key focus area until August 2025, driven by the positive trends in the AI industry chain and the current surge in software applications, indicating potential for further growth in domestic computing power and AI applications [1] - The pharmaceutical and biotechnology sectors, particularly innovative drugs, have shown significant price increases, with a long-term positive trend and some companies still having room for valuation recovery compared to their 2020 peaks [1] - The defense and military industry is expected to receive continuous catalysts, with the current fundamentals and confidence in the military sector being better than in historical years, driven more by fundamental factors than calendar effects [1] Group 2 - The Guotai Science and Technology Innovation Index ETF (589630) tracks the Science and Technology Innovation Index (000680), which can experience daily fluctuations of up to 20%, covering nearly 97% of the market capitalization of the Science and Technology Innovation Board [1] - The index emphasizes technological innovation and growth, with a balanced industry distribution aimed at reflecting the overall performance of the Science and Technology Innovation Board market [1] - Investors without stock accounts can consider the Guotai Science and Technology Innovation Board Comprehensive ETF Initiated Link A (023733) and Link C (023734) [1]

2025年8月11日，南华生物医药股份有限公司与相关方签署《股权收购意向协议》，拟现金收购湖南慧 泽生物医药科技有限公司51%股权，交易完成后慧泽医药将成控股子公司。慧泽医药是专注药物研发及 临床评价的CRO公司，与公司业务协同性强，此次收购旨在完善产业链。交易不构成关联交易，预计 构成重大资产重组，不涉及发行股份及控制权变更。目前意向协议为初步约定，具体交易方案待协商， 最终交易能否达成存在不确定性。公司将依规履行审批及信息披露义务，提醒投资者注意风险。 ...

Market Performance Review - The A-share market experienced a volatile upward trend, reaching new highs, with the CSI 1000 index rising by 2.11%, outperforming other major indices such as the CSI A50 and ChiNext, which increased by 0.64% and 0.49% respectively [12][13] - There was a significant reversal in market style, with cyclical stocks rebounding strongly while the previously resilient consumer style lagged behind [12][13] - All market capitalization styles saw gains, with mid-cap and small-cap indices performing notably better than large-cap indices [12][13] - The performance of core assets and leading growth stocks showed divergence, with the "Ning" combination slightly increasing by 0.07% and the "Mao" index rising by 0.89% [12][13] Industry Analysis - The market's upward movement was primarily driven by event-driven thematic trading, with the defense and military industry leading with a 5.93% increase, followed by significant gains in non-ferrous metals and machinery [4][13] - The defense sector's rise was fueled by China Shipbuilding's announcement on August 5 regarding a stock swap merger with China State Shipbuilding Corporation, which sparked expectations of large-scale restructuring among military-listed companies [4][13] - The only sectors that saw declines were pharmaceuticals, computers, retail, and social services [4][13] Future Outlook and Investment Views - The report emphasizes the importance of both rhythm and direction during the current gap between policy and performance, noting that the recent Central Political Bureau meeting did not indicate large-scale stimulus plans, and the focus will shift more towards demand recovery rather than supply-side reductions [29][30] - The current market rally, which began at the end of June, can be understood as a two-phase structure driven by bank dividends and the transition from "anti-involution" themes, but the potential for further gains may be limited as the appeal of bank dividends diminishes [29][30] - The report suggests a return to growth trading, with individual stock alpha logic taking precedence over industry beta logic, highlighting opportunities for valuation recovery in technology growth sectors such as AI applications, computing power chains, and optical modules [30]

平安证券(香港)研究也指出，当前港股市场仍具有较低估值以及"赚钱效应"下的交易渐趋活跃等优势， 中长期走势仍可保持乐观展望。建议继续关注人工智能、机器人、半导体、工业软件等新质生产力等科 技板块，及政策加力支持的创新医药板块以及具有消费属性的中医药和医疗板块。 本文转载自"腾讯自选股"，智通财经编辑：李佛。 国泰海通发布研报称，尽管6月下旬以来港股相对偏震荡，港股科技相较于创新药等阶段性跑输。但港 股科技、消费类资产与当前AI应用、新消费等产业趋势相关度更高，且基本面更优，相较A股而言仍具 有稀缺性。因此，港股科技、消费、红利等稀缺性资产在宏观偏弱环境下仍具备较强吸引力。预计下半 年港股互联网巨头或将加大AI基础设施领域的资本投入，大模型迭代与AI应用落地进度有望提速。随 着本轮AI浪潮的产业周期向上趋势进一步确认，有望推动相关的港股科技龙头重新跑赢市场。 中信证券研报称，行情的定位决定了主导资金的行为，资金的行为决定了上涨的行业结构及模式。历史 上增量流动性驱动的行情中，领涨行业大都是持续集中，而不是高切低轮动;背后的本质是资金对效率 的追逐，更倾向于高共识品种，而非在低位品种里"蹲变化"。7月的行情演绎也 ...

Group 1 - The stock price of Kanglong Chemical is reported at 28.90 yuan, down 1.83% from the previous trading day, with a trading volume of 1.184 billion yuan [1] - The company operates in the medical services sector as a CRO (Contract Research Organization), providing drug research and development services across various fields including laboratory chemistry, biological sciences, and clinical research services [1] - On August 7, the company stated on an interactive platform that the impact of the US tariffs on its business is limited, as the export of commercial goods constitutes a small portion of its operations [1] Group 2 - On August 7, the net outflow of main funds was 159 million yuan, with a cumulative net outflow of 471 million yuan over the past five trading days [2]

| 603538 | 美诺华 | -5.28 | 13.44 | -7141.76 | | --- | --- | --- | --- | --- | | 000953 | 河化股份 | 1.00 | 21.58 | -6783.63 | | 688222 | 成都先导 | -3.49 | 6.59 | -6676.58 | | 300363 | 博腾股份 | -1.62 | 4.18 | -6054.08 | | 600196 | 复星医药 | -0.98 | 1.29 | -5749.1 1 | | 688185 | 康希诺 | -2.80 | 5.15 | -5649.33 | | 688131 | 皓元医药 | -2.95 | 3.76 | -5426.18 | | 300683 | 海特生物 | -3.97 | 13.76 | -5362.08 | | 688553 | 汇宇制药 | -1.87 | 2.83 | -5128.77 | | 301096 | 百诚医药 | -2.81 | 6.89 | -4796.39 | | 300149 | 睿智医药 | -1.65 | 8.06 | -3859. ...

Market Performance - The A-share market opened higher on August 7, with the Shanghai Composite Index closing up 0.16% at 3639.67 points, reaching a new high for the period [1] - The Shenzhen Component Index and the ChiNext Index closed down 0.18% and 0.68%, at 11157.94 points and 2342.86 points respectively [1] Sector Performance - Sectors such as rare earth permanent magnets, small metals, and jewelry showed significant gains [1] - Conversely, sectors like Contract Research Organizations (CRO), heparin concepts, and innovative drugs experienced notable declines [1] Stock Performance - A total of 2118 stocks in the A-share market rose, with 73 stocks hitting the daily limit up [1] - On the other hand, 3086 stocks declined, with 8 stocks hitting the daily limit down [1] Trading Volume - The trading volume in the Shanghai market reached 749.7 billion yuan, while the Shenzhen market saw a trading volume of 1075.79 billion yuan, totaling approximately 1.83 trillion yuan across both markets [1]

A股三大指数涨跌不一，截至收盘，沪指涨0.16%，深成指跌0.18%，创业板指跌0.68%，北证50指数平 收，沪深京三市成交额18525亿元，较上日放量932亿元。两市超2100只个股上涨。 板块题材上，半导 体、医疗器械、稀土永磁板块走高，CRO、创新药板块调整。 盘面上，半导体板块震荡走强，大为股 份、斯达半导涨停封板，富满微20CM封板。医疗器械板块冲高回落，利德曼、赛诺医疗、中红医疗 20CM涨停，大博医药涨停封板。稀土永磁板块午后走强，正海磁材20CM涨停，宁波韵升涨停封板。 CRO板块走弱，美诺华跌超5%。创新药板块走低，千红制药跌停。 ...

Market Overview - A-shares experienced fluctuations in the morning session but showed significant recovery before noon, with total market turnover exceeding 1.2 trillion yuan, an increase of over 130 billion yuan compared to the previous day [1] - The semiconductor and medical device sectors saw gains, while the CRO and small metal sectors underwent adjustments [1] - The Hong Kong market rebounded from a dip, led by semiconductor stocks [1] Index Performance - By midday, the CSI A500 index decreased by 0.1%, the CSI 300 index increased by 0.1%, the ChiNext index fell by 0.5%, the STAR Market 50 index rose by 0.7%, and the Hang Seng China Enterprises Index increased by 0.4% [1] ETF Composition - The ChiNext ETF tracks the ChiNext index, which consists of 100 stocks with high market capitalization and liquidity, with a significant proportion in strategic emerging industries, including electric equipment, pharmaceuticals, and electronics, accounting for over 55% [3] - The STAR Market 50 ETF tracks the STAR Market 50 index, composed of 50 stocks with high market capitalization and liquidity, prominently featuring technology leaders, with semiconductors making up over 60% and combined with medical devices, software development, and photovoltaic equipment industries accounting for over 75% [3]